MX2015017257A - Composiciones y metodos de inmunizar contra clostridium difficile. - Google Patents

Composiciones y metodos de inmunizar contra clostridium difficile.

Info

Publication number
MX2015017257A
MX2015017257A MX2015017257A MX2015017257A MX2015017257A MX 2015017257 A MX2015017257 A MX 2015017257A MX 2015017257 A MX2015017257 A MX 2015017257A MX 2015017257 A MX2015017257 A MX 2015017257A MX 2015017257 A MX2015017257 A MX 2015017257A
Authority
MX
Mexico
Prior art keywords
difficile
toxin
methods
compositions
subject
Prior art date
Application number
MX2015017257A
Other languages
English (en)
Spanish (es)
Inventor
Pietrobon Patricia
Foglia Ginamarie
De Bruyn Guy
Gurunathan Sanjay
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51168412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015017257(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of MX2015017257A publication Critical patent/MX2015017257A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2015017257A 2013-06-14 2014-06-13 Composiciones y metodos de inmunizar contra clostridium difficile. MX2015017257A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361835246P 2013-06-14 2013-06-14
PCT/US2014/042298 WO2014201346A1 (en) 2013-06-14 2014-06-13 Compositions and methods of immunizing against c. difficile

Publications (1)

Publication Number Publication Date
MX2015017257A true MX2015017257A (es) 2016-11-11

Family

ID=51168412

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015017257A MX2015017257A (es) 2013-06-14 2014-06-13 Composiciones y metodos de inmunizar contra clostridium difficile.

Country Status (12)

Country Link
US (4) US9730994B2 (enExample)
EP (1) EP3007724B1 (enExample)
JP (1) JP6691477B2 (enExample)
KR (1) KR20160020543A (enExample)
CN (1) CN105611942A (enExample)
AU (1) AU2014277981B2 (enExample)
BR (1) BR112015031088A2 (enExample)
CA (1) CA2915279A1 (enExample)
MX (1) MX2015017257A (enExample)
SG (1) SG11201510166YA (enExample)
TW (1) TWI648063B (enExample)
WO (1) WO2014201346A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
SG11201510166YA (en) 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
MX2020003756A (es) * 2017-09-28 2020-07-29 Pfizer Composiciones y metodos para obtener una respuesta inmune contra clostridium difficile.
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071759A (en) 1986-05-30 1991-12-10 The United States Of America As Represented By The Secretary Of The Army Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
EP2305303A3 (en) 1997-10-20 2013-11-13 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
AU2008299885C1 (en) * 2007-09-14 2015-06-25 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing clostridium difficile toxoids A and B
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
GB201206070D0 (en) 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
HK1213917A1 (zh) 2013-03-15 2016-07-15 Sanofi Pasteur, Inc. 類霉素、組合物及相關方法
KR20150133770A (ko) * 2013-03-15 2015-11-30 사노피 파스퇴르 인코포레이티드 톡소이드, 조성물 및 관련 방법
SG11201510166YA (en) 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile

Also Published As

Publication number Publication date
TWI648063B (zh) 2019-01-21
US20170304423A1 (en) 2017-10-26
US20210145956A1 (en) 2021-05-20
WO2014201346A1 (en) 2014-12-18
EP3007724A1 (en) 2016-04-20
JP6691477B2 (ja) 2020-04-28
BR112015031088A2 (pt) 2017-07-25
US20200113991A1 (en) 2020-04-16
US11419930B2 (en) 2022-08-23
US9730994B2 (en) 2017-08-15
KR20160020543A (ko) 2016-02-23
US20160120968A1 (en) 2016-05-05
TW201536314A (zh) 2015-10-01
JP2016521754A (ja) 2016-07-25
CN105611942A (zh) 2016-05-25
CA2915279A1 (en) 2014-12-18
SG11201510166YA (en) 2016-01-28
AU2014277981A1 (en) 2016-01-07
AU2014277981B2 (en) 2019-06-20
EP3007724B1 (en) 2023-07-05

Similar Documents

Publication Publication Date Title
EP4218807A3 (en) Zika virus vaccine
PH12017502233A1 (en) Formulations for neoplasia vaccines and methods of preparing thereof
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
PH12016500773A1 (en) Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants or young children born by c-section
MX351074B (es) Vacunas contra clostridium difficile que comprenden toxinas recombinantes.
PL3003330T3 (pl) Terapia przywracająca mikrobiota (MRT), kompozycje i sposoby wytwarzania
PH12014501041A1 (en) Vaccines directed against human enteroviruses
WO2012170753A3 (en) Bovine vaccines and methods
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
PH12015501716A1 (en) Anti-mycoplasma spp. subunit vaccine
BR112015008417A8 (pt) composição imunogênica, vacina, e, uso de uma composição imunogênica
EA201690997A1 (ru) Композиция для применения в лечении стойкого кашля
PH12015501333B1 (en) Method of making a mycoplasma vaccine
ZA201701000B (en) Attenuated bovine coronavirus and related vaccines
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
MX2015003765A (es) Arterivirus.
BR112015031088A2 (pt) composições e métodos de imunização contra c. difficile
WO2015051371A3 (en) Haemophilus parasuis vaccine serovar type four
MX364946B (es) Sistema adyuvante mejorado para la administración de vacunas orales.
MX2017013564A (es) Formulaciones de glucopiranosil lipido a y alérgenos de cacahuete para administración sublingual.
WO2013173256A3 (en) New and improved influenza vaccines
MX2021003908A (es) Polipeptidos de accion prolongada y metodos para su produccion y administracion.
TR201904585T4 (tr) Göz yorgunluğu ve rahatsızlığını bertaraf etmek ve hafifletmek için göz ferahlatıcı madde.
MX2017016858A (es) Composiciones inmunogenicas.
PH12016502302A1 (en) Pharmaceutical composition for preventing and treating senile dementia and preparation method thereof